IMCR News and Press, Immunocore Holdings plc From 11/09/22

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity data for IMC-F106C, the first off-the-shelf TCR therapy targe...

Summary Immunocore Holdings plc has one asset already in the market. It has a pipeline of TCR bispecific molecules targeting various indications. Immunocore Holdings looks attractive. Immunocore Holdings plc ( IMCR ) is a midcap company with an approved drug and ...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

The following slide deck was published by Immunocore Holdings plc in conjunction with this event. For further details see: Immunocore (IMCR) Presents at ESMO Congress 2022

U.K.-based biotech Immunocore Holdings plc ( NASDAQ: IMCR ) dropped ~24% on Friday after the company announced initial data for its off-the-shelf T cell receptor immunotherapy IMC-F106C from a Phase 1 trial involving patients with solid tumors. A bi-specific protein based on...

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress D ata from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3 ImmTAC, activates T cells and is well ...

The following slide deck was published by Immunocore Holdings plc in conjunction with their 2022 Q2 earnings call. For further details see: Immunocore Holdings plc 2022 Q2 - Results - Earnings Call Presentation

Immunocore Holdings (IMCR) Q2 2022 Earnings Conference Call August 09, 2022, 08:00 ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO & Director Brian Di Donato - CFO & Head, Strategy Ralph Torbay - Head, Commercial David Ber...

Immunocore press release ( NASDAQ: IMCR ): Q2 GAAP EPS of -$0.17. Revenue of $38.92M (+392.7% Y/Y). For further details see: Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® ( tebentafusp ) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp ...